(Total Views: 933)
Posted On: 08/23/2021 9:28:19 PM
Post# of 149001
August Presentation Break Down:
(It’s important to note that Statins are expensive or cause many symptoms similar to Long Haulers.)
“It is important to note that in people living with HIV, the occurrence of NAFLD (NASH) is higher than in the general population, affecting 30 to 65 percent of the HIV population1.” -NP
I see this drug as preventing Nash patients just like I see Leronlimab as potentially preventing LH in Severe / Critical when given 4 or more doses. Because we know that in 14 days, the viral load is NOT reduced to Zero.
“we have not observed the hepatoxicity that has been evident in other CCR5 antagonists and HIV medications. We see leronlimab as potentially anchoring a patient’s HIV treatment regimen, or as a monotherapy HIV drug, designed to protect the liver, maintain and regain liver health, and protect healthy cells from HIV entry.”
This is why the difference between 350Mg, 525Mg, and 700Mg is important! To protect the LIVER to help these other indications other drugs create. Pairing 350Mg with other medications is not the way. “The FDA sees the data and how some patients didn’t respond to 350Mg but did with 525Mg…” -NP
The popular other ccr5 antagonist mentioned often is Maraviroc (if you didn’t know), that also has FDA black box warnings.
In fact, because Leronlimab is not in pill form, that’s why it works so well.
“Gastric acids may prevent or slow the breakdown of certain medications. Additionally, when a medication is metabolized in the liver, its potency will DECREASE along with its EFFECTIVENESS before the therapeutic reaches the bloodstream.”
So, it wouldn’t be so thoughtful to be investing into a pill form of Leronlimab.
“Medications that HIV patients take as part of their regimen may cause fatty liver development and have other hepatoxic effects.”
Leronlimab isn’t just going to be an HIV drug (God Willing), or a drug that cuts off the blood supply to tumors, but it’s going to be something that likely decreases fat deposits in humans which then rids the need for Statins and other ccr5 antagonist.
“CytoDyn previously published data showing that leronlimab completely blocked Xeno-GvHD in these humanized mice. Daniel Lindner, M.D., Ph.D. of the Cleveland Clinic, who conducted the studies, stated: “Our results showed that leronlimab effectively inhibited fatty liver development, the hallmark of early stages of NASH.”
Basically, from what I see our Insulin Receptors become less responsive with Nash / LH (or other HIV antagonist).
This causes fat droplets to form and grow, even entering the blood steam. Inflammation grows and it leads to NASH…then fibrosis (scar tissue). Resulting in liver enzymes increasing AST/ ALT, increasing lgm.
lgM is the body's first line of defense against a foreign antigen.
lgG is another class of antibodies that appears later and gradually replaces the lgM antibodies.
(The MRI shows tumor pvalue - .0023 in cancer)
Lgm, This inflammation-caused cellular damage can trigger diseases like “diabetes, cancer, dementia, heart disease, arthritis and depression. “
What was presented in the August presentation? MS-Alzheimer-Stroke Phase 2. Which will likely generate a BTD in the future.
What’s quite significant of my findings is that it’s believed to also be linked to Asthma. I’m short, this will be HUGE in sports and people who suffer from Asthma in highly polluted cities or countries like Los Angeles and India.
I’m summary, LL may not only be preventive to HIV (Prep) but also Nash, And LH.
I believe LH to show more symptoms than Nash itself, but ultimate lead to Nash. LH might be a “mild” form of Nash in the future with Leronlimab as an early and late stages of treatment.
“NALFD is the most common form of chronic liver disease, affecting about 30 to 40 percent of the population in the United States5”
AND
With 10-30% of Covid patients developing LH, CytoDyn is set to rule the world. Right now Big Pharmas are the Malls (huge and a commodity) but, CytoDyn will likely be the Amazon of Big Pharmas.
(It’s important to note that Statins are expensive or cause many symptoms similar to Long Haulers.)
“It is important to note that in people living with HIV, the occurrence of NAFLD (NASH) is higher than in the general population, affecting 30 to 65 percent of the HIV population1.” -NP
I see this drug as preventing Nash patients just like I see Leronlimab as potentially preventing LH in Severe / Critical when given 4 or more doses. Because we know that in 14 days, the viral load is NOT reduced to Zero.
“we have not observed the hepatoxicity that has been evident in other CCR5 antagonists and HIV medications. We see leronlimab as potentially anchoring a patient’s HIV treatment regimen, or as a monotherapy HIV drug, designed to protect the liver, maintain and regain liver health, and protect healthy cells from HIV entry.”
This is why the difference between 350Mg, 525Mg, and 700Mg is important! To protect the LIVER to help these other indications other drugs create. Pairing 350Mg with other medications is not the way. “The FDA sees the data and how some patients didn’t respond to 350Mg but did with 525Mg…” -NP
The popular other ccr5 antagonist mentioned often is Maraviroc (if you didn’t know), that also has FDA black box warnings.
In fact, because Leronlimab is not in pill form, that’s why it works so well.
“Gastric acids may prevent or slow the breakdown of certain medications. Additionally, when a medication is metabolized in the liver, its potency will DECREASE along with its EFFECTIVENESS before the therapeutic reaches the bloodstream.”
So, it wouldn’t be so thoughtful to be investing into a pill form of Leronlimab.
“Medications that HIV patients take as part of their regimen may cause fatty liver development and have other hepatoxic effects.”
Leronlimab isn’t just going to be an HIV drug (God Willing), or a drug that cuts off the blood supply to tumors, but it’s going to be something that likely decreases fat deposits in humans which then rids the need for Statins and other ccr5 antagonist.
“CytoDyn previously published data showing that leronlimab completely blocked Xeno-GvHD in these humanized mice. Daniel Lindner, M.D., Ph.D. of the Cleveland Clinic, who conducted the studies, stated: “Our results showed that leronlimab effectively inhibited fatty liver development, the hallmark of early stages of NASH.”
Basically, from what I see our Insulin Receptors become less responsive with Nash / LH (or other HIV antagonist).
This causes fat droplets to form and grow, even entering the blood steam. Inflammation grows and it leads to NASH…then fibrosis (scar tissue). Resulting in liver enzymes increasing AST/ ALT, increasing lgm.
lgM is the body's first line of defense against a foreign antigen.
lgG is another class of antibodies that appears later and gradually replaces the lgM antibodies.
(The MRI shows tumor pvalue - .0023 in cancer)
Lgm, This inflammation-caused cellular damage can trigger diseases like “diabetes, cancer, dementia, heart disease, arthritis and depression. “
What was presented in the August presentation? MS-Alzheimer-Stroke Phase 2. Which will likely generate a BTD in the future.
What’s quite significant of my findings is that it’s believed to also be linked to Asthma. I’m short, this will be HUGE in sports and people who suffer from Asthma in highly polluted cities or countries like Los Angeles and India.
I’m summary, LL may not only be preventive to HIV (Prep) but also Nash, And LH.
I believe LH to show more symptoms than Nash itself, but ultimate lead to Nash. LH might be a “mild” form of Nash in the future with Leronlimab as an early and late stages of treatment.
“NALFD is the most common form of chronic liver disease, affecting about 30 to 40 percent of the population in the United States5”
AND
With 10-30% of Covid patients developing LH, CytoDyn is set to rule the world. Right now Big Pharmas are the Malls (huge and a commodity) but, CytoDyn will likely be the Amazon of Big Pharmas.
(28)
(1)Scroll down for more posts ▼
